Kempharm, INC: directors' dealings · United States · SEC (Form 4)

About Kempharm, INC

KemPharm, Inc. (ticker KMPH) is a U.S.-based biopharmaceutical company that was historically focused on the discovery and development of prodrug-based therapies, especially for central nervous system disorders and rare diseases. Founded in 2006 in the United States, the company built its strategy around its proprietary Ligand Activated Therapy (LAT®) platform, which was designed to optimize existing molecules and improve their clinical profile, duration of action, or potential tolerability. Over time, KemPharm shifted its corporate center to Florida, while retaining historical operational links to Iowa. Its principal executive offices have been reported in Celebration, Florida, United States. From a public-market perspective, KemPharm was listed on NASDAQ under the symbol KMPH. For French-speaking investors, that means the company has been a U.S.-listed issuer subject to SEC disclosure standards, including insider transaction reporting on Form 4. KemPharm went public in 2015 and later underwent significant strategic changes, including a broader pivot toward rare-disease drug development. Historically, the company’s portfolio included several assets aimed at ADHD and other CNS-related conditions. The best-known approved product was AZSTARYS®, a once-daily ADHD treatment for patients aged six years and older. The pipeline also included clinical-stage programs such as KP1077 for idiopathic hypersomnia and narcolepsy, plus other assets targeting stimulant use disorder and additional unmet needs in CNS therapeutics. In parallel, KemPharm sought to monetize its LAT® platform through licensing and commercialization partnerships, which is a common strategy for specialty biopharma companies with limited internal sales infrastructure. In competitive terms, KemPharm operated in a highly crowded market where it faced competition from large pharmaceutical groups and niche specialty biotech players in ADHD, sleep disorders, and rare diseases. Its main differentiation was not scale, but intellectual property, platform technology, and the ability to structure partnering transactions around its prodrug expertise. For equity investors, this typically implies a high-risk, event-driven biotech profile, with valuation sensitivity to clinical data, regulatory milestones, and partner execution. A major recent milestone was the company’s name change to Zevra Therapeutics, Inc. in February 2023, signaling a broader strategic repositioning into rare disease. Even so, the KemPharm name remains highly relevant in historical SEC filings and market references associated with KMPH. In short, KMPH corresponds to an American Health Care / Biopharma story built around proprietary drug-delivery science, specialty CNS assets, and a later transition toward a more diversified rare-disease platform.